Gene sequencing technology company 10x Genomics (NASDAQ: TXG) hasn't been having it easy in the past few days on the stock market. A bearish analyst move dampened sentiment on the company ...

That occurred on Monday, when Tejas Savant from white-shoe investment bank Morgan Stanley reduced his 10x Genomics price target to $18 per share, far down from his previous level of $26.

The sequencing process was carriedout on a NovaSeq 6000 sequencer, whereas alignment and gene count was performed using 10X Genomics Cell Ranger 7.0.0 and the ... the European Research Council (ERC) ...

10x Genomics (TXG) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is ...

Illumina is suing Element Biosciences, with the sequencing giant accusing its smaller rival of infringing on five of its patents covering flow cell and ... as 10x Genomics did by pursuing patent ...

10x Genomics says it eliminated 8% of its workforce ... Sales of 10x’s Chromium single-cell analysis products fell 25%, to $5.913 million from $7.85 million, while spatial instrument sales ...

The government had launched a public consultation on the issue in 2021. 10x Genomics and Bruker, which owns NanoString Technologies, have signed a global cross-license agreement, ending all pending ...

Bruker and 10x Genomics have agreed to settle a patent dispute relating to products originally developed by Nanostring, a company Bruker acquired in 2024. Under the settlement, whose financial ...

Human umbilical cord blood (hUCB) was obtained from a healthy newborn delivered at the Department of Obstetrics and Gynecology, Medical University of Warsaw (Warsaw Bioethics Committee permission ...